Alirocumab

Papers on alirocumab

58 papers33 new in 30 days

Wednesday, November 18

Thursday, November 12

Tuesday, November 10

Monday, November 9

AHA Scientific Sessions 2026 Abstract

Weighted blood marker better predicted heart and stroke risk

Absolute reductions in the risk of heart and stroke events with alirocumab versus placebo ranged from 0.5 to 4 percentage points across the marker’s range.Absolute reductions in the risk of heart and stroke events with alirocumab versus placebo ranged from 0.5 to 4 percentage points across the marker’s range.

Blood-fat particles form a dense cluster beside a smaller, sparser cluster, surrounded by blood cells, a heart, and a brain.
Randomized trial · 11,957 peopleBiomarkers
AHA Scientific Sessions 2026 Abstract

Evolocumab linked to fewer deaths in high-risk adults

Over three years, deaths occurred in 1.4% of evolocumab users versus 2.7% of alirocumab users across 2,610 matched pairs.Over three years, deaths occurred in 1.4% of evolocumab users versus 2.7% of alirocumab users across 2,610 matched pairs.

Artery cross-sections contain plaque and contrasting sparse and dense cholesterol particles, surrounded by small upright, faceless people.
Cohort studyEvolocumab

Saturday, November 7

Friday, November 6

Monday, November 2

Thursday, October 29

Monday, October 26